Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 5/2017

24.11.2016 | Review Article

A consensus statement on the gender perspective in lung cancer

verfasst von: D. Isla, M. Majem, N. Viñolas, A. Artal, A. Blasco, E. Felip, P. Garrido, J. Remón, M. Baquedano, J. M. Borrás, M. Die Trill, R. García-Campelo, O. Juan, C. León, P. Lianes, F. López-Ríos, L. Molins, M. Á. Planchuelo, M. Cobo, L. Paz-Ares, J. M. Trigo, J. de Castro

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Lung cancer is the most common cancer globally and has the highest mortality. Although this disease is not associated with a particular gender, its incidence is rising among women, who are diagnosed at an increasingly younger age compared with men. One of the main reasons for this rise is women taking up smoking. However, many non-smoking women also develop this disease. Other risk factors implicated in the differential development of lung cancer in women are genetic predisposition, tumour histology and molecular profile. Proportionally more women than men with lung cancer have a mutation in the EGFR gene. This consensus statement reviews the available evidence about the epidemiological, biological, diagnostic, therapeutic, social and psychological aspects of lung cancer in women.
Literatur
1.
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.CrossRefPubMed
2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
3.
Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26:779–86.CrossRefPubMed
4.
5.
Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, et al. Lung cancer in women: an overview with special focus on Spanish women. Clin Transl Oncol. 2014;16:517–28.PubMed
6.
7.
8.
9.
Cleries R, Buxo M, Martinez JM, Espinas JA, Dyba T, Borras JM. Contribution of changes in demography and in the risk factors to the predicted pattern of cancer mortality among Spanish women by 2022. Cancer Epidemiol. 2016;40:113–8.CrossRefPubMed
10.
Schiaffino A, Fernandez E, Borrell C, Salto E, Garcia M, Borras JM. Gender and educational differences in smoking initiation rates in Spain from 1948 to 1992. Eur J Pub Health. 2003;13:56–60.CrossRef
11.
Linares I, Molina-Portillo E, Exposito J, Baeyens JA, Suarez C, Sanchez MJ. Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985–2012: a population-based study. Clin Transl Oncol. 2016;18:489–96.CrossRefPubMed
12.
Lopez MJ, Perez-Rios M, Schiaffino A, Fernandez E. Mortality attributable to secondhand smoke exposure in Spain (2011). Nicotine Tob Res. 2016;18:1307–10.CrossRefPubMed
13.
Kreuzer M, Boffetta P, Whitley E, Ahrens W, Gaborieau V, Heinrich J, et al. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer. 2000;82:227–33.CrossRefPubMed
14.
Galcerán J, Ameijide A, Carulla M, Mateos A, Quirós JR, Alemán A et al. Estimaciones de la incidencia y la supervivencia del cáncer en España y su situación en Europa. Red Española de Registros de Cáncer (REDECAN) 2014.
15.
Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008;9:649–56.CrossRefPubMedPubMedCentral
16.
Rouquette I, Lauwers-Cances V, Allera C, Brouchet L, Milia J, Nicaise Y, et al. Characteristics of lung cancer in women: importance of hormonal and growth factors. Lung Cancer. 2012;76:280–5.CrossRefPubMed
17.
Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gend Med. 2010;7:381–401.CrossRefPubMed
18.
Pesatori AC, Carugno M, Consonni D, Caporaso NE, Wacholder S, Tucker M, et al. Reproductive and hormonal factors and the risk of lung cancer: the EAGLE study. Int J Cancer. 2013;132:2630–9.CrossRefPubMed
19.
Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88:183–92.CrossRefPubMed
20.
Marrogi AJ, Mechanic LE, Welsh JA, Bowman ED, Khan MA, Enewold L, et al. TP53 mutation spectrum in lung cancer is not different in women and men. Cancer Epidemiol Biomarkers Prev. 2005;14:1031–3.CrossRefPubMed
21.
Dogan S, Shen R, Ang DC, Johnson ML, D’Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169–77.CrossRefPubMedPubMedCentral
22.
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10:768–77.CrossRefPubMedPubMedCentral
23.
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415–26.CrossRefPubMed
24.
Sacher AG, Dahlberg SE, Heng J, Mach S, Janne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2016;2:313–20.CrossRefPubMedPubMedCentral
25.
Conde E, Angulo B, Izquierdo E, Munoz L, Suarez-Gauthier A, Plaza C, et al. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology. 2013;62:609–16.CrossRefPubMed
26.
Martinez P, Hernandez-Losa J, Montero MA, Cedres S, Castellvi J, Martinez-Marti A, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS ONE. 2013;8:e52261.CrossRefPubMedPubMedCentral
27.
Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014;9:295–306.CrossRefPubMed
28.
Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget. 2015;6:10577–85.CrossRefPubMedPubMedCentral
29.
Clave S, Gimeno J, Munoz-Marmol AM, Vidal J, Reguart N, Carcereny E, et al. ROS1 copy number alterations are frequent in non-small cell lung cancer. Oncotarget. 2016;7:8019–28.PubMedPubMedCentral
30.
Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, et al. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology. 2014;65:187–94.CrossRefPubMed
31.
Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, et al. Clinicopathological characteristics of RET rearranged lung cancer in european patients. J Thorac Oncol. 2016;11:122–7.CrossRefPubMed
32.
Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910–8.CrossRefPubMed
33.
Mazieres J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27:281–6.CrossRefPubMed
34.
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016:[Epub ahead of print].
35.
36.
Sriram N, Mills J, Lang E, Dickson HK, Hamann HA, Nosek BA, et al. Attitudes and stereotypes in lung cancer versus breast cancer. PLoS ONE. 2015;10:e0145715.CrossRefPubMedPubMedCentral
37.
Cataldo JK, Brodsky JL. Lung cancer stigma, anxiety, depression and symptom severity. Oncology. 2013;85:33–40.CrossRefPubMed
38.
LoConte NK, Else-Quest NM, Eickhoff J, Hyde J, Schiller JH. Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer. Clin Lung Cancer. 2008;9:171–8.CrossRefPubMed
39.
Cella DF, Orofiamma B, Holland JC, Silberfarb PM, Tross S, Feldstein M, et al. The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer. 1987;60:1661–7.CrossRefPubMed
40.
Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18:893–903.CrossRefPubMed
41.
Hill KM, Amir Z, Muers MF, Connolly CK, Round CE. Do newly diagnosed lung cancer patients feel their concerns are being met? Eur J Cancer Care (Engl). 2003;12:35–45.CrossRef
42.
Svobodnik A, Yang P, Novotny PJ, Bass E, Garces YI, Jett JR, et al. Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin Proc. 2004;79:1024–30.CrossRefPubMed
43.
Sarna L, Brown JK, Cooley ME, Williams RD, Chernecky C, Padilla G, et al. Quality of life and meaning of illness of women with lung cancer. Oncol Nurs Forum. 2005;32:E9–19.CrossRefPubMed
44.
Brown JK, Cooley ME, Chernecky C, Sarna L. A symptom cluster and sentinel symptom experienced by women with lung cancer. Oncol Nurs Forum. 2011;38:E425–35.CrossRefPubMed
45.
Badr H, Smith CB, Goldstein NE, Gomez JE, Redd WH. Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: results of a randomized pilot trial. Cancer. 2015;121:150–8.CrossRefPubMed
46.
Ferrell BR, Virani R, Grant M. Analysis of symptom assessment and management content in nursing textbooks. J Palliat Med. 1999;2:161–72.CrossRefPubMed
47.
Sarna L, Cooley ME, Brown JK, Williams RD, Chernecky C, Padilla G, et al. Quality of life and health status of dyads of women with lung cancer and family members. Oncol Nurs Forum. 2006;33:1109–16.CrossRefPubMed
48.
Hagedoorn M, Buunk BP, Kuijer RG, Wobbes T, Sanderman R. Couples dealing with cancer: role and gender differences regarding psychological distress and quality of life. Psychooncology. 2000;9:232–42.CrossRefPubMed
49.
Vinolas N, Magem M, Garrido P, Artal A, de Castro J, Campelo RG et al. Lung cancer in women: The Spanish female-specific database WORLD 07. J Clin Oncol. 2009;27:15 s (Abstract 8084).
50.
51.
Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22:2277–85.CrossRefPubMedPubMedCentral
52.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.CrossRefPubMed
53.
Tammemagi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11:e1001764.CrossRefPubMedPubMedCentral
54.
55.
Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.CrossRefPubMed
56.
Cueto A, Quero F, Bayarri CI, Izquierdo C, Izquierdo JM, Fibla JJ et al., editors. Características diferenciales de la cirugía del carcinoma broncogénico en la mujer y sus complicaciones postoperatorias. 7 Congreso de la Sociedad Espaola de Ciruga Torcica; 2016; Valencia, Spain.
57.
Debieuvre D, Oster JP, Riou R, Berruchon J, Levy A, Mathieu JP, et al. The new face of non-small-cell lung cancer in men: results of two French prospective epidemiological studies conducted 10 years apart. Lung Cancer. 2016;91:1–6.CrossRefPubMed
58.
Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–92.CrossRefPubMed
59.
Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1:441–6.CrossRefPubMed
60.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.CrossRefPubMed
61.
Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20–30.CrossRefPubMed
62.
Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Future Oncol. 2015;11:1245–57.CrossRefPubMed
63.
Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in egfr-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33:1958–65.CrossRefPubMed
64.
Fan L, Feng Y, Wan H, Shi G, Niu W. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS ONE. 2014;9:e100866.CrossRefPubMedPubMedCentral
65.
Fallet V, Cadranel J, Doubre H, Toper C, Monnet I, Chinet T, et al. Prospective screening for ALK: clinical features and outcome according to ALK status. Eur J Cancer. 2014;50:1239–46.CrossRefPubMed
66.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.CrossRefPubMed
67.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.CrossRefPubMed
68.
Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol. 2015;10:1396–403.CrossRefPubMed
69.
Chen D, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, et al. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9:e101354.CrossRefPubMedPubMedCentral
70.
Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, et al. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncol. 2015;10:1451–7.CrossRefPubMed
71.
Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992–9.CrossRefPubMed
72.
Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721–30.CrossRefPubMed
73.
Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21:4014–21.CrossRefPubMed
74.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.CrossRefPubMed
75.
Hoensch H, Morgenstern I, Petereit G, Siepmann M, Peters WH, Roelofs HM, et al. Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut. 2002;50:235–40.CrossRefPubMedPubMedCentral
76.
Peccatori FA, Azim HA, Jr., Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi160–70.
77.
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.CrossRefPubMedPubMedCentral
78.
Bermejo B, Navarro B, Lluch A. Cáncer y fertilidad. ARBOR Ciencia, Pensamiento y Cultura. 2015;191:a239.
79.
80.
Pollán M, Planchuelo A, Campelo RG, López Ríos F, Gómez J, Trigo JM, et al. Cáncer de Pulmón en Mujeres. ICAPEM: Aspectos Diferenciales; 2015.
Metadaten
Titel
A consensus statement on the gender perspective in lung cancer
verfasst von
D. Isla
M. Majem
N. Viñolas
A. Artal
A. Blasco
E. Felip
P. Garrido
J. Remón
M. Baquedano
J. M. Borrás
M. Die Trill
R. García-Campelo
O. Juan
C. León
P. Lianes
F. López-Ríos
L. Molins
M. Á. Planchuelo
M. Cobo
L. Paz-Ares
J. M. Trigo
J. de Castro
Publikationsdatum
24.11.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1578-x

Weitere Artikel der Ausgabe 5/2017

Clinical and Translational Oncology 5/2017 Zur Ausgabe

Research Article

Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer

Research Article

MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1

Research Article

CDK4 in lung, and head and neck cancers in old age: evaluation as a biomarker

Erratum

Erratum to: Gastrointestinal stromal tumors (GISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis

Research Article

Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy

Research Article

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen